{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:21:24Z","timestamp":1786965684953,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Here, we used bio-informatic tools to identify novel targets involved in DNA repair and epigenetics and which are associated with high-risk myeloma. The prognostic significance of the target genes was analyzed using publicly available gene expression data of MM patients (TT2\/3 and HM cohorts). Hence, protein arginine methyltransferase 5 (PRMT5) was identified as a promising target. Druggability was assessed in OPM2, JJN3, AMO1 and XG7 human myeloma cell lines using the PRMT5-inhibitor EPZ015938. EPZ015938 strongly reduced the total symmetric-dimethyl arginine levels in all cell lines and lead to decreased cellular growth, supported by cell line dependent changes in cell cycle distribution. At later time points, apoptosis occurred, as evidenced by increased AnnexinV-positivity and cleavage of PARP and caspases. Transcriptome analysis revealed a role for PRMT5 in regulating alternative splicing, nonsense-mediated decay, DNA repair and PI3K\/mTOR-signaling, irrespective of the cell line type. PRMT5 inhibition reduced the expression of upstream DNA repair kinases ATM and ATR, which may in part explain our observation that EPZ015938 and the DNA-alkylating agent, melphalan, have combinatory effects. Of interest, using a low-dose of mTOR-inhibitor, we observed that cell viability was partially rescued from the effects of EPZ015938, indicating a role for mTOR-related pathways in the anti-myeloma activity of EPZ015938. Moreover, PRMT5 was shown to be involved in splicing regulation of MMSET and SLAMF7, known genes of importance in MM disease. As such, we broaden the understanding of the exact role of PRMT5 in MM disease and further underline its use as a possible therapeutic target.<\/jats:p>","DOI":"10.3389\/fcell.2022.879057","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T07:17:29Z","timestamp":1654672649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach"],"prefix":"10.3389","volume":"10","author":[{"given":"Philip","family":"Vlummens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"Verhulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"De Boussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/neuonc\/nox206","article-title":"PRMT5 as a Druggable Target for Glioblastoma Therapy","volume":"20","author":"Banasavadi-Siddegowda","year":"2018","journal-title":"Neuro Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total Therapy 2 without Thalidomide in Comparison with Total Therapy 1: Role of Intensified Induction and Posttransplantation Consolidation Therapies","volume":"7","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjh.15800","article-title":"Substratification of Patients with Newly Diagnosed Standard\u2010risk Multiple Myeloma","volume":"185","author":"Binder","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene Expression Profiling for Molecular Classification of Multiple Myeloma in Newly Diagnosed Patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/cancers12102996","article-title":"Epigenetic Aberrations in Multiple Myeloma","volume":"12","author":"Caprio","year":"2020","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2018.208306","article-title":"Kinome Expression Profiling to Target New Therapeutic Avenues in Multiple Myeloma","volume":"105","author":"de Boussac","year":"2020","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood-2009-07-232801","article-title":"IGF-1 Suppresses Bim Expression in Multiple Myeloma via Epigenetic and Posttranslational Mechanisms","volume":"115","author":"De Bruyne","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.v92.3.802","article-title":"Presence of a P53 Gene Deletion in Patients with Multiple Myeloma Predicts for Short Survival after Conventional-Dose Chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3324\/haematol.2019.241513","article-title":"Elotuzumab, Lenalidomide, and Dexamethasone as Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 300 Cases outside of Controlled Clinical Trials","volume":"106","author":"Gentile","year":"2021","journal-title":"haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/leu.2017.334.Epub.2017Nov21","article-title":"Protein Arginine Methyltransferase 5 Has Prognostic Relevance and Is a Druggable Target in Multiple Myeloma","volume":"32","author":"Gull\u00e0","year":"2018","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12563.Epub.2013.Sep20","article-title":"Myeloma Stem Cell Concepts, Heterogeneity and Plasticity of Multiple Myeloma","volume":"163","author":"Hajek","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20100","DOI":"10.1073\/pnas.2004112117","article-title":"Lsh\/HELLS Is Required for B Lymphocyte Development and Immunoglobulin Class Switch Recombination","volume":"117","author":"He","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-019-03274-0","article-title":"The Protein Arginine Methyltransferase PRMT5 Confers Therapeutic Resistance to mTOR Inhibition in Glioblastoma","volume":"145","author":"Holmes","year":"2019","journal-title":"J. Neurooncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation Is a Central Independent Prognostic Factor and Target for Personalized and Risk-Adapted Treatment in Multiple Myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of Aurora Kinases for Tailored Risk-Adapted Treatment of Multiple Myeloma","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","article-title":"High-risk Multiple Myeloma: Definition and Management","volume":"17","author":"Joseph","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2004-09-3704","article-title":"Overexpression of Transcripts Originating from the MMSET Locus Characterizes All T(4;14)(p16;q32)-Positive Multiple Myeloma Patients","volume":"105","author":"Keats","year":"2005","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In Multiple Myeloma, T(4;14)(p16;q32) Is an Adverse Prognostic Factor Irrespective of FGFR3 Expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 Function and Targeting in Cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cst"},{"key":"B21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature14351","article-title":"MYC Regulates the Core Pre-mRNA Splicing Machinery as an Essential Step in Lymphomagenesis","volume":"523","author":"Koh","year":"2015","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1172\/JCI61188.Epub.2012.Oct.1","article-title":"Molecular Pathogenesis of Multiple Myeloma and its Premalignant Precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"23343","DOI":"10.1074\/jbc.M113.523423","article-title":"Functional Effects of a Pathogenic Mutation in Cereblon (CRBN) on the Regulation of Protein Synthesis via the AMPK-mTOR Cascade","volume":"289","author":"Lee","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B24","first-page":"212","article-title":"Scutellarin Circumvents Chemoresistance, Promotes Apoptosis, and Represses Tumor Growth by HDAC\/miR-34a-mediated Down-Modulation of Akt\/mTOR and NF-\u039ab-Orchestrated Signaling Pathways in Multiple Myeloma","volume":"13","author":"Li","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","article-title":"PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"B27","first-page":"2579","article-title":"Visualizing Data Using T-SNE","volume":"9","author":"Maaten","year":"2008","journal-title":"J. Mach. Learn Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.18632\/oncotarget.1821","article-title":"The Role of DNA Damage and Repair in Decitabine-Mediated Apoptosis in Multiple Myeloma","volume":"5","author":"Maes","year":"2014","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13059-017-1184-4","article-title":"IRFinder: Assessing the Impact of Intron Retention on Mammalian Gene Expression","volume":"18","author":"Middleton","year":"2017","journal-title":"Genome Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2010.033456","article-title":"A High-Risk Signature for Patients with Multiple Myeloma Established from the Molecular Classification of Human Myeloma Cell Lines","volume":"96","author":"Moreaux","year":"2011","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene Expression Profiling and Correlation with Outcome in Clinical Trials of the Proteasome Inhibitor Bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"18062","DOI":"10.1038\/s41598-019-54407-4","article-title":"Assessment of TP53 Lesions for P53 System Functionality and Drug Resistance in Multiple Myeloma Using an Isogenic Cell Line Model","volume":"9","author":"Munawar","year":"2019","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13046-022-02250-3","article-title":"Pyrroline-5-Carboxylate Reductase 1: a Novel Target for Sensitizing Multiple Myeloma Cells to Bortezomib by Inhibition of PRAS40-Mediated Protein Synthesis","volume":"41","author":"Oudaert","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41594-019-0313-z","article-title":"PRMT5 Methylome Profiling Uncovers a Direct Link to Splicing Regulation in Acute Myeloid Leukemia","volume":"26","author":"Radzisheuskaya","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"11106","DOI":"10.1093\/nar\/gkx727","article-title":"The PRMT5\/WDR77 Complex Regulates Alternative Splicing through ZNF326 in Breast Cancer","volume":"45","author":"Rengasamy","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1038\/onc.2016.116.Epub.2016.Apr.25","article-title":"MMSET\/WHSC1 Enhances DNA Damage Repair Leading to an Increase in Resistance to Chemotherapeutic Agents","volume":"35","author":"Shah","year":"2016","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"v159","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: A Phase I Study of GSK3326595, a First-In-Class Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Advanced Solid Tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8728","DOI":"10.18632\/aging.103198","article-title":"High PRMT5 Expression Is Associated with Poor Overall Survival and Tumor Progression in Bladder Cancer","volume":"12","author":"Tan","year":"2020","journal-title":"Aging"},{"key":"B39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/thno.28374","article-title":"Comprehensive Characterization of the Mutational Landscape in Multiple Myeloma Cell Lines Reveals Potential Drivers and Pathways Associated with Tumor Progression and Drug Resistance","volume":"9","author":"Vikova","year":"2019","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2019.00524","article-title":"NF-\u03baB\/mTOR\/MYC Axis Drives PRMT5 Protein Induction after T Cell Activation via Transcriptional and Non-transcriptional Mechanisms","volume":"10","author":"Webb","year":"2019","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal Selection and Double-Hit Events Involving Tumor Suppressor Genes Underlie Relapse in Myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/636514","article-title":"MMSET: Role and Therapeutic Opportunities in Multiple Myeloma","volume":"2014","author":"Xie","year":"2014","journal-title":"BioMed Res. Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41375-018-0300-0","article-title":"MMSET I Acts as an Oncoprotein and Regulates GLO1 Expression in T(4;14) Multiple Myeloma Cells","volume":"33","author":"Xie","year":"2019","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/ijms22020817","article-title":"Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling","volume":"22","author":"Yan","year":"2021","journal-title":"Ijms"},{"key":"B45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/c5mb00663e","article-title":"ReactomePA: an R\/Bioconductor Package for Reactome Pathway Analysis and Visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol. Biosyst."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1038\/s41375-019-0489-6","article-title":"PRMT5 Is Upregulated by B-Cell Receptor Signaling and Forms a Positive-Feedback Loop with PI3K\/AKT in Lymphoma Cells","volume":"33","author":"Zhu","year":"2019","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon Expression Is Required for the Antimyeloma Activity of Lenalidomide and Pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular Mechanism of Action of Immune-Modulatory Drugs Thalidomide, Lenalidomide and Pomalidomide in Multiple Myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leukemia Lymphoma"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.879057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T07:17:34Z","timestamp":1654672654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.879057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":49,"alternative-id":["10.3389\/fcell.2022.879057"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2022.879057","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"article-number":"879057"}}